Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: Overview of systematic reviews;Eficácia e segurança dos antipsicóticos atípicos (quetiapina, risperidona, aripiprazol, paliperidona) em comparação com um placebo ou medicamentos antipsicóticos típicos no tratamento da esquizofrenia refratária: Overview de revisão sistemática

Sao Paulo Medical Journal

Volumn 128, Issue 3, 2010, Pages 141-166

  Melnik, Tamara ^a   Soares, Bernardo Garcia ^a   Puga, Maria Eduarda dos Santos ^a   Atallah, Álvaro Nagib ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic agents; Opamine antagonists; Quetiapine substance name ; Ripiprazole substance name ; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AKATHISIA; ANXIETY DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIZZINESS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; DYSTONIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKINESIA; HYPERPROLACTINEMIA; INSOMNIA; METABOLIC DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCLE STIFFNESS; NAUSEA; PARKINSONISM; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

EID: 78249269162     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802010000300007     Document Type: Review

References (116)

1. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998; 24(1):75-85.
2. nd ed. Oxford: Blackwell Publishing; 2003. p. 489-516.
3. Altamura AC, Bassetti R, Cattaneo E, Vismara S. Some biological correlates of drug resistance in schizophrenia: a multidimensional approach. World J Biol Psychiatry. 2005; 6 suppl 2:23-30.
4. Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry. 1997; 154(4):475-482.
5. Henna J, Oliveira JR, Mello M F, et al. Predictors of response and outcome in treatment resistant versus non treatment resistant schizophrenic patients. Schizophrenia Research. 1999; 36(1-3):281-282.
6. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antip-sychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence; 2002. Available from: http://www.crd.york.ac.uk/crdweb/ShowRecord. asp?View=Full&ID=32002000858. Accessed in 2010 (Apr 29).
7. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defning treatment refractoriness in schizophrenia. Schizophr Bull. 1990, 16(4):551-561.
8. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9):789-796.
9. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2006; (2):CD004578.
10. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2008; (3):CD006617.
11. Nussbaum AM, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev. 2008;(2):CD006369.
12. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967.
13. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev. 2003;(2):CD000440.
14. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antip-sychotic medication for schizophrenia. Cochrane Database Syst Rev. 2000; (3):CD002306.
15. Jayaram MB. Contributor Hosalli Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006; (2):CD005237.
16. Moher D, Tsertsvadze A, Tricco AC, et al. When and how to update systematic reviews. Co-chrane Database Syst Rev. 2008(1) MR000023.
17. th World Congress of Psychiatry; Aug 24-29; Yokohama, Japan; 2002. [abstract].
18. th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA; 2003. [NR537].
19. th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA; 2004. [APA Conference abstracts NR612].
20. Oren D, Marcus R, Kostic D, et al. Effcacy and Safety of Intramuscular Aripiprazole, Halope-ridol or Placebo in Acutely Agitated Patients with Schizophrenia or Schizoaffective Disorder. In: XX International Congress on Schizophrenia Research; 2005 April 2-6, Georgia, USA; 2005. Schizophrenia Bulletin 2005;31:399. [abstract].
21. th Annual Meeting of the American College of Neuropsychopharmacology; 2000, Dec 10-14; San Juan; Puerto Rico; 2000. [abstract].
22. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Effcacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology. 2000; 10(Suppl 3):S309-310.
23. Csernansky JG. Treatment of schizophrenia: preventing the progression of disease. Psychiatr Clin North Am. 2003; 26(2):367-379.
24. Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsycho-tic: overview of a phase II study result. International Journal of Neuropsychopharmacology. 2000; 3(Suppl 1):S157.
25. Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. International Journal of Neuropsychopharmacology 2002;5(Suppl 1): S186.
26. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008; 69(5):720-731.
27. Kane JM, Meltzer HY, Carson WH Jr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007; 68(2):213-223.
28. Davidson M, Emsley R, Kramer M, et al. Effcacy, safety and early response of paliperido-ne extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007; 93(1-3):117-130.
29. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007; 27(1):6-14.
30. Marder SR, Kramer M, Ford L, et al. Effcacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007; 62(12):1363-1370.
31. th Collegium Internationale Neuro-psychopharma-cologicum; 2006, Jul 9-13; Chicago, Illinois; 2006. [abstract]
32. Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatr Dis Treat. 2008; 4(5):949-958.
33. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166(6):691-701.
34. TM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. European Neurop-sychopharmacology. 1994; 4(3):384-385.
35. Link CGG, Arvanitis L. 'Seroquel' treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens. European Neuropsychopharmacology 1995; 5:346-347.
36. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997; 54(6):549-557.
37. th International Conference on Schizophrenia 1996: Breaking Down the Barriers; 1996, Oct 6-9; Vancouver, Canada; 1996. [abstract].
38. Arvanitis LA, Miller BG. 'Seroquel' (ICI 204,636): an atypical antipsychotic: results from a multiple fxed dose, placebo-controlled study. European Neuropsychopharmacology. 1996; 6(Suppl 3):148.
39. th Annual Meeting of American Psychiatric Association; 1996, May 2-9, New York, New York; 1996. [abstract].
40. th Annual Meeting of the American College of Neurop-sychopharmacology; 1997, Dec 8-12, Waikoloa, Hawaii; 1997. [abstract].
41. Arvanitis LA, Miller BG. Multiple fxed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997; 42(4):233-246.
42. Arvanitis LA, Miller BG, Study Group. ICI 204,636, an atypical antipsychotic: results from a multiple fxed-dose, placebo-controlled trial. Psychopharmacology Bulletin. 1966;32:391.
43. Borison RL, Arvanitis LA, Miller BG. A comparison of fve fxed doses of 'seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia. Schizophrenia Research. 1996;18(2-3):132.
44. Borison RL, Arvanitis LA, Miller BG. A multiple fxed-dose, placebo-controlled trial with 'sero-quel' - An atypical antipsychotic. Biological Psychiatry. 1996; 39(7):597-598.
45. th Annual Meeting of the American Association for Geriatric Psychiatry; 1998, Mar 8-11, San Diego, California; 1998. [abstract].
46. st Annual Meeting of the American Psychiatric Association; 1998, May 30 - Jun 4, Toronto, Ontario; 1998. [abstract].
47. st Annual Meeting of the American Psychiatric Association; 1998, May 30 - Jun 4, Toronto, Ontario; 1998. [abstract].
48. Hong WW, Arvanitis LA, Miller BG. 'Seroquel' (ICI 204,636): not different from placebo for EPS or prolactin. Biological Psychiatry. 1996;39:598.
49. Hong WW, Arvanitis LA, Miller BG. 'Seroquel' (ICI 204-636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin. European Neuropsychopharmacology. 1996;6(Suppl 3):171.
50. th Annual Meeting of the American Psychiatric Association; 1996, May 2-9, New York, New York; 1996. [abstract].
51. th Annual Meeting of the American College of Neuropsychopharmacology; 1995, Dec 11-15, San Juan, Puerto Rico; 1995. [abstract].
52. Fabre L F, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and effcacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995; 17(3):366-378.
53. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: effcacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psycho-pharmacol. 1996; 16(2):158-169.
54. TM in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia. European Neuropsychopharmacology. 1994; 4(3):385.
55. TM treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens. European Neuropsychopharmacology. 1995; 5(3):346-347.
56. Barzega G, Bogetto F, Maina G, Ravizza L. [Effcacia e tollerabilita dell' antipsychotico atipico quetiapina: uno studio in doppio cieco]. Minerva Psichiatrica 1999; 40:297-305.
57. Barzega G, Bogetto F, Maina G, Ravizza L. Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison. European Journal of Psychiatry 2000; 14:221-232.
58. th Annual Meeting of the American College of Neuropsychopharmacology; 1995, Dec 11-15, San Juan, Puerto Rico; 1995. [abstract].
59. King DJ, Link CGC. 'Seroquel' (ICI 204636): an atypical antipsychotic - results from Phase III. European Neuropsychopharmacology 1996; 6:202.
60. th Collegium Internationale Neuro-psychopharmacologicum; 1996, June 23-27, Melbourne, Australia; 1996. [abstract].
61. King DJ, Link CG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Se-roquel) in the treatment of schizophrenia. Psychopharmacology (Berl). 1998; 137(2):139-146.
62. Reuther E, Degner D. Results of a multicenter study comparing the dosage and the dosage regimen of ICI 204,636 ('Seroquel'). Nervenarzt 1996; 67:S192.
63. Purdon SE, Malla A, Labelle A, Litt W. Long-term treatment of quetiapine improves cognitive function in schizophrenia. Biological Psychiatry. 2000; 47(8 Suppl 1):S42.
64. Purdon SE, Malla A, Labelle A, Litt W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001; 26(2):137-149.
65. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med. 2000; 30(1):95-105.
66. Fleishhacker W, Link C, Hurst B. ICI 204,636 (Seroquel) - a putative new antipsychotic: results from Phase III trials. Schizophrenia Research 1996; 18:32.
67. Hellewell JSE, Hurst BC, Link CGG. Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('Seroquel'-ICI 204,636). European Neuropsychopharmacolo-gy 1996; 6:123.
68. th World Congress of Psychiatry; 1996, Aug 23-28, Madrid, Spain; 1996. [abstract].
69. Empfeld JR, Clayton J, Isaac M, et al. AstraZeneca AB. Metabotropic glutamate receptor-potentiating isoindolones. [Patent application]. Available from: http://www.faqs.org/patents/ app/20090149505. Accessed in 2010 (May 27).
70. TM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. European Neuropsychopharmacolo-gy. 1994; 4(3):385.
71. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997; 96(4):265-273.
72. Buckley P F, Goldstein JM, Emsley RA. Comparison of quetiapine and haloperidol in treatment-resistant schizophrenia. In: Annual Meeting of the American Psychiatric Association; 2001, May 5-10; Los Angeles, USA; 2001. [abstract].
73. Emsley RA, Bailey P, Jones AM, Raniwalla JTI. Effcacy of quetiapine fumarate in partial responders. In: Annual Meeting of the American Psychiatry Association; 1999, Washington, USA; 1999. [abstract].
74. Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: effcacy of quetiapine versus haloperidol. European Neuropsychopharmacology 2001; 11:S264.
75. Emsley RA, Raniwalla J, Bailey P, Jones AM. [Effcacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment]. European Neuropsychopharmacology. 1999;9(Suppl 5):S267.
76. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000; 15(3):121-131.
77. Emsley RA, Raniwalla J, Jones AM, PRIZE Study Group. Effcacy of seroquel in treating all of the positive and negative symptoms of schizophrenia. Schizofrenia Research. 2000;41(1):203.
78. th Annual Meeting of the American College of Neuropsychopharmacology; 2000, Dec 10-14; San Juan, Puerto Rico; 2000. [abstract].
79. Nasrallah HA, Rennie P, Altman C. Patterns of response in patients with schizophrenia partially responsive to fuphenazine and switched to quetiapine or haloperidol. European Neu-ropsychopharmacology. 2001; 11(Suppl 3):S262.
80. Weiden PJ, Ashworth P. Switching from fuphenazine to quetiapine ameliorates extrapyrami-dal symptoms and neuroendocrine side effects in patients with schizophrenia. European Neuropsychopharmacology. 2001; 11(Suppl 3):S262-S263.
81. Kudo Y, Nomura J, Ikawa G, et al. Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double-blind controlled study using mosapramine hydrochloride as a control. Rinsyo Iyaku. 2000; 16:1807-42.
82. Kudo Y, Nomura J, Ikawa G, et al. Clinical trial of quetiapine in schizophrenia - effcacy and tolerability of quetiapine: a comparative double-blind study with masopramine in schizophrenic patients. In: Annual Meeting of the World Psychiatric Association; 1999, Aug 6-11; Hamburg, Germany; 1999. [abstract].
83. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, effcacy, and tolera-bility of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001; 23(11):1839-1854.
84. Tandon R. Quetiapine and risperidone in outpatients with schizophrenia: subanalysis of the QUEST trial. In: Annual Meeting of the American Psychiatric Association; 2001, May 5-10; Los Angeles, USA; 2001. [abstract].
85. Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fuphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005; 28(4):163-168.
86. Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetia-pine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007; 24(1):1-13.
87. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, ha-loperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996; 16(1):38-44.
88. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fxed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993; 13(1):25-40.
89. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparitive study. Acta Psychiatr Scand. 1992; 85(4):295-305.
90. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993; 88(6):395-402.
91. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand. 1995; 91(4):271-277.
92. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151(6):825-835.
93. Min SK, Rhee CS, Kim CE, Kang DY. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993; 34(2):179-190.
94. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995; 166(6):712-726; discussion 727-33.
95. th Annual Meeting of the American Psychiatric Association; 1997, May 17-22; San Diego, California; 1997. [abstract].
96. th CINP Congress; 1998, July 12-16, Glasgow, Scotland; 1998. [abstract].
97. th CINP Congress; 1998, July 12-16, Glasgow, Scotland; 1998. [abstract].
98. rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002, Jun 23-27; Montreal, Canada; 2002. [abstract].
99. Namjoshi M, Young Cm, Huang L, Edgell ET, Breier A. Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial. Eur Neuropsychopharmacol. 2002; (Suppl 3): S315.
100. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olan-zapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001; 158(5):765-774.
101. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003; 11(6):638-647.
102. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus rispe-ridone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychophar-macol. 1997; 17(5):407-418.
103. Lieberman JA, Stroup TS, McEvoy J P, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-1223.
104. Keefe RS, Young CA, Rock SL, et al. One-year double-blind study of the neurocognitive effcacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006; 81(1):1-15.
105. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000; 57(3): 249-258.
106. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharma-cology. 2003; 28(1):182-192.
107. Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev. 2003; (4):CD004161.
108. Kane JM, Eerdekens M, Lindenmayer J P, et al. Long-acting injectable risperidone: effcacy and safety of the frst long-acting atypical antipsychotic. Am J Psychiatry. 2003; 160(6): 1125-1132.
109. Suzuki T, Uchida H, Watanabe K, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperi-done for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2008; 23(6):455-463.
110. Freudenreich O, Henderson DC, Walsh J P, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007; 92(1-3):90-94.
111. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006; 32(4):715-723.
112. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006; 354(5):472-482.
113. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166(2):152-163.
114. Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatr. 2005; 27(3): 178-184.
115. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in frst-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet. 2008; 371(9618):1085-1097.
116. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009; 35(2):443-457.